8/4/2020 4:16:06 PM
Rigel Q2 Net Loss $17.6 Mln Or $0.10/Shr Vs Net Loss $20.6 Mln Or $0.12/Shr Last Year
7/27/2020 7:32:32 AM
Rigel Says Post-hoc Data Analysis Of TAVALISSE In Adult Patients With Immune Thrombocytopenia Published
7/14/2020 7:31:51 AM
Rigel Announces Initiation Of Investigator-Sponsored Trial Of Fostamatinib In Patients With COVID-19 Pneumonia
7/9/2020 8:20:52 AM
Rigel Pharma Announces Availability Of TAVLESSE In Europe
5/5/2020 4:03:06 PM
Rigel Pharma Q1 EPS $0.13 Vs. Loss $0.11 Year Ago
2/27/2020 4:05:30 PM
Rigel Q4 Loss/share $0.10 Vs. Profit $0.02 Year Ago
1/13/2020 7:33:06 AM
Rigel Pharma Posts Q4 TAVALISSE Preliminary Net Product Sales Of About $13.8 Mln
12/17/2019 5:01:39 PM
Rigel Pharmaceuticals Announces Resignation Of Eldon Mayer As Chief Commercial Officer